MEI Pharma Stock Forecast, Price & News

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma or view top-rated stocks.

What stocks does MarketBeat like better than MEI Pharma?

Wall Street analysts have given MEI Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MEI Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for MEI Pharma.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Tuesday, September, 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.12. The business earned $10.12 million during the quarter, compared to the consensus estimate of $5.18 million. MEI Pharma had a negative net margin of 198.06% and a negative trailing twelve-month return on equity of 80.62%.
View MEI Pharma's earnings history.

How has MEI Pharma's stock been impacted by COVID-19 (Coronavirus)?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MEIP stock has increased by 85.8% and is now trading at $2.88.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MEIP?

7 brokers have issued 12-month target prices for MEI Pharma's shares. Their forecasts range from $8.00 to $20.00. On average, they expect MEI Pharma's share price to reach $11.00 in the next year. This suggests a possible upside of 281.9% from the stock's current price.
View analysts' price targets for MEI Pharma or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:

• Daniel P. Gold, President, Chief Executive Officer & Director
• David M. Urso, Chief Operating Officer & General Counsel
• Brian G. Drazba, Chief Financial Officer & Secretary
• Richard G. Ghalie, Chief Medical Officer
• Tina C. Beamon, Chief Compliance Officer

Who are some of MEI Pharma's key competitors?

Some companies that are related to MEI Pharma include COMPASS Pathways (CMPS), Connect Biopharma (CNTB), Arcturus Therapeutics (ARCT), Avid Bioservices (CDMO), Y-mAbs Therapeutics (YMAB), Axsome Therapeutics (AXSM), MacroGenics (MGNX), Heron Therapeutics (HRTX), Kronos Bio (KRON), Northwest Biotherapeutics (NWBO), Innoviva (INVA), Olema Pharmaceuticals (OLMA), MannKind (MNKD), ImmunoGen (IMGN) and Enanta Pharmaceuticals (ENTA).
View all of MEIP's competitors.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (6.21%), BlackRock Inc. (6.10%), Wasatch Advisors Inc. (5.90%), Vanguard Group Inc. (4.67%), BVF Inc. IL (3.14%) and Woodline Partners LP (2.10%). Company insiders that own MEI Pharma stock include Brian G Drazba, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma.

Which major investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Goldman Sachs Group Inc., Vanguard Group Inc., Bank of America Corp DE, Point72 Asset Management L.P., Connor Clark & Lunn Investment Management Ltd., and BVF Inc. IL.
View insider buying and selling activity for MEI Pharma or view top insider-selling stocks.

Which major investors are buying MEI Pharma stock?

MEIP stock was purchased by a variety of institutional investors in the last quarter, including Woodline Partners LP, Altium Capital Management LP, First Light Asset Management LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Panagora Asset Management Inc., Wells Fargo & Company MN, and Squarepoint Ops LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.88.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $324.51 million and generates $25.53 million in revenue each year. The company earns $-50,580,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 369-7100 or via email at [email protected].